A Review of Canadian Medical School Conflict of Interest Policies

DOI: 10.4236/ce.2013.43032   PDF   HTML     3,277 Downloads   5,026 Views  


Background:Growing evidence of behavioral bias has caused a surge of interest in the area of Conflict of Interest (COI) within the medical community. The present study sought to evaluate the landscape of Faculty of Medicine COI policies among Canadian medical schools using an evaluation system adapted from the AMSA PharmFree Scorecard.Methods:The authors contacted leaders at the CPD/CME offices of all 17 Canadian medical schools in 2011 to determine how many had formal policies guiding interaction with the pharmaceutical industry. Existing policies were evaluated based on 16 criteria developed by a steering committee. A Policy Score was calculated and a letter grade assigned for each of the existing policies.Results:At the time of review, roughly 35% of the Canadian medical schools had faculty-wide COI policy/guidelines, half of which hadbeen implemented. Other policies are currently in development. Policy Scores ranged from 25.00% to 70.83% with a Mean Policy Score of 52.08%. Policies that were implemented all scored higher than those that were not implemented. Additionally, several strengths and weaknesses among policies were identified.Conclusions:Canadian schools have recognized that COI and bias have becomea serious issue and are taking stepstoward its management. The authors propose that the CMFS employ a system similar to the AMSA Scorecard to evaluate progress in a longitudinal study.

Share and Cite:

Beyaert, M. , Takhar, J. , Dixon, D. , Steele, M. , Isserlin, L. , Garcia, C. , Pereira, I. and Eadie, J. (2013) A Review of Canadian Medical School Conflict of Interest Policies. Creative Education, 4, 217-222. doi: 10.4236/ce.2013.43032.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Adair, R. F., & Holmgren, L. R. (2005). Do drug samples influence resident prescribing behavior? A randomized trial. The American Journal of Medicine, 118, 881-884. doi:10.1016/j.amjmed.2005.02.031
[2] Association of American Medical Colleges (AAMC) (2008). Industry funding of medical education: report of an AAMC task force. URL (last checked 2 March 2013). https://members.aamc.org/eweb/upload/Industry%20Funding%20of%20Medical%20Education.pdf
[3] American Medical Student Association (AMSA) (2012). AMSA PharmFree scorecard 2011-2012. URL (last checked 2 March 2013). http://www.amsascorecard.org
[4] Bekelman, J. E., Li, Y., & Gross, C. P. (2003). Scope and impact of financial conflicts of interest in biomedical research: A systematic review. Journal of the American Medical Association, 289, 454-465. doi:10.1001/jama.289.4.454
[5] Brennan, T. A., Rothman, D. J., Blank, L., Blumenthal, D., Chimonas, S. C., Cohen, J. J., Goldman, J., Kassirer, J. P., Kimball, H., Naughton, J., & Smelser, N. (2006). Health industry practices that create conflicts of interest. A policy proposal for academic medical centers. Journal of the American Medical Association, 295, 429-433. doi:10.1001/jama.295.4.429
[6] Canadian Foundation of Medical Students (CFMS) (2011). Defining the relationship: An evidence based review and recommendations on the role of industry funding in medical schools. URL (last checked 2 March 2013). http://www.cfms.org/attachments/article/163/cfms_industry_funding_working_group_paper.pdf
[7] Canadian Medical Association (CMA) (2007). Guidelines for physiccians in interactions with industry: CMA Policy. URL (last checked 2 March 2013). http://policybase.cma.ca/dbtw-wpd/Policypdf/PD08-01.pdf
[8] Chimonas, S., Patterson, L., Raveis, V. H., & Rothman, D. J. (2011). Managing conflicts of interest in clinical care: A national survey of policies at US medical schools. Academic Medicine, 86, 293-299. doi:10.1097/ACM.0b013e3182087156
[9] Choudhry, N. K., Stelfox, H. T., & Detsky, A. S. (2002). Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association, 287, 612- 617. doi:10.1001/jama.287.5.612
[10] Dana, J., & Loewenstein, G. (2003) A social science perspective on gifts to physicians from industry. Journal of the American Medical Association, 290, 252-255. doi:10.1001/jama.290.2.252
[11] Gangon, M. A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditure in the United States. PLOS Medicine, 5, 29-33.
[12] Institutes of Medicine (IOM) (2009). Conflict of interest in medical research, education, and practice. URL (last checked 2 March 2013). http://www.nap.edu/catalog.php?record_id=12598
[13] Lexchin, J., Bero, L. A., Djubegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ, 326, 1167-1170. doi:10.1136/bmj.326.7400.1167
[14] Lexchin, J., Sekeres, M., Gold, J., Ferris, L.E., Kalkar, S. R., Wu, W., Van Laethem, M., Chan, A. W., Mohen, D., Maskalyk, M. J., Taback, N., & Rochon, P. A. (2008). National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centers. Journal of General Internal Medicine, 23, 1896-1903. doi:10.1007/s11606-008-0752-4
[15] Mathieu, G., Smith, E., Potvin, M. J., & Williams-Jones, B. (2012). Conflict of interest policies at Canadian universities and medical schools: Some lessons learned from the AMSA PharmFree Scorecard. Bioethique Online, 1, 1-11.
[16] McCormick, B. B., Tomlinson, G., Brill-Edwards, P., & Detsky, A. S. (2001). Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post training attitudes and behavior. Journal of the American Medical Association, 286, 1994-1999. doi:10.1001/jama.286.16.1994
[17] Morgan, M. A., Dana, J., Loewenstein, G., Zinberg, S., & Schulkin, J. (2006). Interactions of doctors with the pharmaceutical industry. Journal of Medical Ethics, 32, 559-563. doi:10.1136/jme.2005.014480
[18] Neuman, J., Korenstein, D., Ross, J. S., & Keyhani, S. (2011). Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: Cross sectional study. BMJ, 343, d5621. doi:10.1136/bmj.d5621
[19] Okike, K., Kocher, M. S., Wei, E. X., Mehlman, C. T., & Bhandari, M. (2009). Accuracy of conflict-of-interest disclosures reported by physicians. The New England Journal of Medicine, 361, 1466-1474. doi:10.1056/NEJMsa0807160
[20] Rochon, P. A., Sekeres, M., Hoey, J., Lexchin, J., Ferris, L. E., Moher, D., Wu, W., Kalkar, S. R., Van Laethem, M., Gruneir, A., Gold, J., Maskalyk, J., Streiner, D. L., Taback, N., & Chan, A. W. (2011). Investigator experiences with financial conflicts of interest in clinical trials. Trials, 12, 1-9. doi:10.1186/1745-6215-12-9
[21] Smith, E., & Williams-Jones, B (2009). Legalistic or inspirational? Comparing university conflict of interest policies. Higher Education Policy, 22, 433-459. doi:10.1057/hep.2009.3
[22] Standing Committee on Continuing Professional Development (SCCPD) (2010). SCCPD position paper on the role of industry in university-based CME/CPD Offices and Industry Relations. URL (last checked 2 March 2013). http://www.afmc.ca/pdf/committees/SCCPD_Position_Paper_on_Role_of_Industry_in_
[23] Thompson, D. (1993). Understanding financial conflicts of interest. New England Journal of Medicine, 329, 573-576. doi:10.1056/NEJM199308193290812
[24] Wazana, A. (2000). Physicians and the pharmaceutical industry. Is a gift every just a gift? Journal of the American Medical Association, 283, 373-380. doi:10.1001/jama.283.3.373
[25] Williams-Jones, B., & MacDonald, C. (2008). Conflict of interest policies at Canadian universities: clarity and content. Journal of Academic Ethics, 6, 79-90. doi:10.1007/s10805-007-9052-6
[26] Zipkin, D. A., & Steinman, M. A. (2005). Interactions between pharmaceutical representatives and doctors in training: A thematic review. Journal of General Internal Medicine, 20, 777-786. doi:10.1111/j.1525-1497.2005.0134.x

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.